# Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million
Canonical URL: https://biopharmsignal.com/news/CLRB/cellectar-biosciences-announces-oversubscribed-financing-up-to-140-million
Ticker: CLRB
Company: Cellectar Biosciences
Source: Cellectar Biosciences
Published: 2026-05-05 11:00 EST
Original Source URL: https://www.cellectar.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-01 12:05 EST — [Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-to-highlight-compelling-new-efficacy-data-from-phase-2b-clover-wam-study-of-iopofosine-i-131-in-r-r-waldenstroem-macroglobulinemia-at-the-american-society-of-clinical-oncology-annual-meeting) — Source: Cellectar Biosciences
- 2026-05-14 11:15 EST — [Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-reports-first-quarter-2026-financial-results-and-provides-corporate-updates) — Source: Cellectar Biosciences
- 2026-05-11 12:05 EST — [Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-to-report-first-quarter-financial-results-and-host-a-conference-call-on-thursday-may-14-2026) — Source: Cellectar Biosciences
- 2026-05-05 11:10 EST — [Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenström Macroglobulinemia](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-reports-positive-12-month-follow-up-data-from-phase-2b-clover-wam-study-demonstrating-durable-responses-and-efficacy-of-iopofosine-i-131-in-r-r-waldenstroem-macroglobulinemia) — Source: Cellectar Biosciences
- 2026-05-05 11:00 EST — [Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million](https://biopharmsignal.com/news/CLRB/cellectar-biosciences-announces-oversubscribed-financing-up-to-140-million) — Source: Cellectar Biosciences
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)